CliCAR:一种非遗传CAR工程策略,以赋予NK细胞针对癌症免疫疗法的能力
Su Yeon Lim1, Yeongbeom Kim1, Seungmin Han2
1Department of Smart Health Science and Technology, Kangwon National University, Chuncheon 24341, Republic of Korea.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|October 30, 2025
概括
一种基于蛋白质的新疗法,即重组化学抗原受体融合蛋白 (CliCAR),使自然杀手 (NK) 细胞能够在不进行基因编辑的情况下向HER2阳性癌症. 这种非病毒性方法为强效,现成的免疫细胞疗法提供了安全,快速的策略.
科学领域:
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
- 生物技术是生物技术.
背景情况:
- 传统的基于化学抗原受体 (CAR) 的免疫疗法在血液癌症中显示出有效性.
- 自然杀手 (NK) 细胞中的低病毒载体转导效率限制了CAR治疗的应用.
- 基因工程和病毒传递对基于CAR的免疫疗法构成挑战.
研究的目的:
- 开发一种非病毒平台,用于在免疫细胞中快速表达CAR.
- 在CAR自然杀手 (NK) 细胞治疗中克服病毒载体的局限性.
- 建立一个安全,高效和可定制的CAR交付方法.
主要方法:
- 开发一种重组化学抗原受体融合蛋白 (CliCAR) 平台.
- 使用CliCAR对NK细胞进行非遗传修饰以表达CAR.
- 在异种移植模型中评估细胞毒性,免疫激活 (IFN-γ, perforin,granzyme B) 和体内疗效.
主要成果:
- 快速内化和局部化到NK细胞膜,赋予CAR功能.
- 克里卡-NK细胞对HER2阳性癌细胞具有选择性细胞毒性.
- 在体内研究显示显著抑制HER2阳性瘤生长,没有可观察到的毒性.
结论:
- 该CliCAR系统提供了一个新的,基于蛋白质的CAR表达策略.
- 这种非病毒,非基因编辑方法能够快速产生CAR-NK细胞.
- CliCAR提供了一个安全,可定制和强大的平台,用于针对各种癌症,包括固体瘤的现成免疫细胞疗法.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Cytotoxic T Cells-mediated Immune Response
6.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
6.4K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


